Egrifta, also known as tesamorelin, is a prescription medication used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a condition characterized by abnormal fat distribution in the body, often seen in individuals living with HIV who are taking antiretroviral medications.

Egrifta works by stimulating the production of growth hormone, which in turn helps to reduce visceral adipose tissue, or excess fat around the abdomen. By targeting this specific type of fat, Egrifta can help improve the appearance and overall health of individuals with HIV-related lipodystrophy.

It is important to note that Egrifta is not a cure for lipodystrophy, but rather a treatment option to help manage the symptoms associated with the condition. As with any medication, there may be potential side effects to be aware of, including injection site reactions, joint pain, and muscle aches.

Before starting Egrifta, it is essential to consult with a healthcare provider to determine if this medication is appropriate for your individual needs and medical history. Your healthcare provider will be able to provide guidance on proper dosing, administration, and monitoring while taking Egrifta.

Overall, Egrifta can be a valuable tool in the management of HIV-related lipodystrophy, helping individuals to feel more comfortable in their own skin and improve their quality of life. If you have any questions or concerns about Egrifta, do not hesitate to reach out to your healthcare provider for more information.